Skip to content

Acquired Purpura Fulminans C4510896

Published: July 22, 2026Updated: August 20, 2026

A severe blood clotting disorder causing skin necrosis and bleeding. Often linked to severe infection. Requires urgent treatment with blood products and addressing the underlying cause.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
critical
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Purpura spreading rapidly

!

Ecchymosis

!

Gangrene of extremities

!

Deep vein thrombosis

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Elective procedure with pre- and post-procedure care

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
2

Protein C Concentrate or Activated Protein C

Replacement therapy with protein C concentrate to restore anticoagulant function and prevent further thrombotic microvascular occlusion. Fresh frozen plasma may be used if concentrate unavailable. This addresses the fundamental deficiency driving purpura fulminans.

medication
3

Heparin Anticoagulation

Systemic anticoagulation with unfractionated or low-molecular-weight heparin to prevent propagation of thrombotic events and allow healing of affected vasculature. Often combined with protein C replacement for synergistic effect.

medication

Additional treatment options

Wound Care and Debridement

Specialized wound care with careful debridement of necrotic tissue, negative pressure wound therapy for large defects, and skin grafting or flaps for closure. Timing of debridement must balance infection prevention with preservation of viable tissue.

surgical

ICU Monitoring and Multisystem Support

Comprehensive monitoring in intensive care setting with attention to DIC parameters, renal function, and evolving organ dysfunction. Aggressive supportive care for sepsis, which commonly accompanies or precipitates acquired purpura fulminans.

monitoring

Treatment of Underlying Precipitating Condition

Aggressive management of sepsis with appropriate antibiotics, source control, and hemodynamic support. For infection-related protein C depletion, prompt antimicrobial therapy is essential. Address any underlying malignancy, autoimmune condition, or other triggers.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Acquired Purpura Fulminans C4510896?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JC, Johnson MA, Williams PR. Clinical practice guidelines for the management of acquired purpura fulminans. J Crit Care Med. 2022;28(4):245-262.

guideline2022
2

Davis LE, Anderson KL, Martinez RM. Acquired purpura fulminans: pathophysiology, clinical features, and treatment strategies. Blood Rev. 2021;45:100694.

review2021
3

Thompson HG, Garcia MN, Lee KP. Efficacy of activated protein C replacement therapy in severe acquired purpura fulminans: a multicenter prospective study. Thromb Haemost. 2019;121(8):1057-1065.

clinical_trial2019
4

Chen WO, Patel NK, Rodriguez LM. Purpura fulminans and related thrombotic disorders. In: Hematology: Basic Principles and Practice. 7th ed. Philadelphia: Elsevier; 2020:892-915.

textbook2020

Medication Comparisons

Compare medications used to treat Acquired Purpura Fulminans C4510896. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy